XLA-associated neutropenia treatment: A case report and review of the literature

Zachary David Jacobs, Jesus Ramon Guajardo, Katherine Marie Anderson

Research output: Contribution to journalArticle

18 Scopus citations

Abstract

X-linked agammaglobulinemia (XLA) is a primary B-cell deficiency syndrome with an incidence of 5 to 10 cases per million. The current treatment approach includes intravenous immunoglobulin and aggressive antibiotic regimens for infections. Besides recurrent infections, XLA patients may present with other manifestations, such as alopecia, enteropathy, amyloidosis, and neutropenia. Neutropenia, which has been shown in up to 25% of affected patients, might also contribute to the degree of severity of bacterial infections that have been reported in these cases. Here we present our experience with the granulocyte colony-stimulant factor, filgrastim (Neupogen), in the treatment of neutropenia in a 14-month-old child with XLA.

Original languageEnglish (US)
Pages (from-to)631-634
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume30
Issue number8
DOIs
StatePublished - Aug 1 2008

    Fingerprint

Keywords

  • Bruton's
  • Filgrastim
  • G-CSF
  • Neupogen
  • Neutropenia
  • X-linked agammaglobulinemia
  • XLA

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this